Osteoporosis in post-menopausal women (PMO) remains a leading cause of morbidity worldwide. Ibandronic acid, a nitrogen-containing bisphosphonate, has been extensively studied in this population. Available as a 150 mg once-monthly oral tablet or a 3 mg quarterly intravenous (IV) infusion,1,2 ibandronic acid offers flexible dosing regimens that align with patient preferences and clinical circumstances. In this article, we review its mechanism of action, benefits in fracture prevention, impact on bone mineral density (BMD) and turnover markers, factors influencing patient adherence, and its safety profile, based on data from key clinical trials and real-world evidence.
Login to read more
